Literature DB >> 25395045

Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.

L Luckenbaugh1, K M Kitrinos, W E Delaney, J Hu.   

Abstract

Complete virions of hepatitis B virus (HBV) contain a DNA genome that is enclosed in a capsid composed of the HBV core antigen (HBcAg), which is in turn surrounded by a lipid envelope studded with viral surface antigens (HBsAg). In addition, HBV-infected cells release subviral particles composed of HBsAg only (HBsAg 'spheres' and 'filaments') or HBsAg enveloping HBcAg but devoid of viral DNA ('empty virions'). The hepatitis B e antigen (HBeAg), a soluble antigen related to HBcAg, is also secreted in some HBV-infected patients. The goals of this study were to explore the levels of empty virions in HBV-infected patients before and during therapy with the nucleotide analog tenofovir disoproxil fumarate (TDF) that inhibits HBV DNA synthesis and the relationships of empty virions to complete virions, HBsAg and HBeAg. HBV DNA, HBcAg and HBsAg levels were determined in serum samples from 21 patients chronically infected with HBV and enrolled in clinical TDF studies. Serum levels of empty virions were found to exceed levels of DNA-containing virions, often by ≥ 100-fold. Levels of both empty and complete virions varied and were related to the HBeAg status. When HBV DNA replication was suppressed by TDF, empty virion levels remained unchanged in most but were decreased (to the limit of detection) in some patients who also experienced significant decrease or loss of serum HBsAg. In conclusion, empty virions are present in the serum of chronic hepatitis B patients at high levels and may be useful in monitoring response to antiviral therapy.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  cccDNA; empty hepatitis B virion; hepatitis B core antigen; hepatitis B e antigen; nucleotide analog

Mesh:

Substances:

Year:  2014        PMID: 25395045      PMCID: PMC4500509          DOI: 10.1111/jvh.12361

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  38 in total

1.  Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.

Authors:  Matsuo Deguchi; Naoko Yamashita; Masanori Kagita; Seishi Asari; Yoshinori Iwatani; Takahiko Tsuchida; Kazushige Iinuma; Isa K Mushahwar
Journal:  J Virol Methods       Date:  2004-02       Impact factor: 2.014

2.  Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA.

Authors:  S Staprans; D D Loeb; D Ganem
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  Native hepatitis B virions and capsids visualized by electron cryomicroscopy.

Authors:  Kelly A Dryden; Stefan F Wieland; Christina Whitten-Bauer; John L Gerin; Francis V Chisari; Mark Yeager
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

4.  Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy.

Authors:  J F Conway; N Cheng; A Zlotnick; P T Wingfield; S J Stahl; A C Steven
Journal:  Nature       Date:  1997-03-06       Impact factor: 49.962

5.  Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies.

Authors:  Fabien Zoulim; Barbara Testoni; Fanny Lebossé
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-16       Impact factor: 11.382

6.  Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis.

Authors:  T Gerelsaikhan; J E Tavis; V Bruss
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Authors:  R J Colonno; E V Genovesi; I Medina; L Lamb; S K Durham; M L Huang; L Corey; M Littlejohn; S Locarnini; B C Tennant; B Rose; J M Clark
Journal:  J Infect Dis       Date:  2001-10-29       Impact factor: 5.226

8.  Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.

Authors:  Thomas Berg; Fabien Zoulim; Bernd Moeller; Huy Trinh; Patrick Marcellin; Sing Chan; Kathryn M Kitrinos; Phillip Dinh; John F Flaherty; John G McHutchison; Michael Manns
Journal:  J Hepatol       Date:  2013-12-01       Impact factor: 25.083

9.  Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.

Authors:  Jesse Summers; William S Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  Hepatitis B surface antigen produced by a human hepatoma cell line.

Authors:  G M MacNab; J J Alexander; G Lecatsas; E M Bey; J M Urbanowicz
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

View more
  32 in total

1.  In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.

Authors:  Xiaonan Zhang; Wei Lu; Ye Zheng; Weixia Wang; Lu Bai; Liang Chen; Yanling Feng; Zhanqing Zhang; Zhenghong Yuan
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 2.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

Review 3.  Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.

Authors:  Fengmin Lu; Jie Wang; Xiangmei Chen; Dongping Xu; Ningshao Xia
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

4.  Detection of Hepatitis B Virus Particles Released from Cultured Cells by Particle Gel Assay.

Authors:  Ran Yan; Dawei Cai; Yuanjie Liu; Haitao Guo
Journal:  Methods Mol Biol       Date:  2017

5.  An Aptamer against the Matrix Binding Domain on the Hepatitis B Virus Capsid Impairs Virion Formation.

Authors:  Ahmed Orabi; Maria Bieringer; Arie Geerlof; Volker Bruss
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

6.  Capsid Phosphorylation State and Hepadnavirus Virion Secretion.

Authors:  Xiaojun Ning; Suresh H Basagoudanavar; Kuancheng Liu; Laurie Luckenbaugh; Duoqian Wei; Chunyan Wang; Bo Wei; Yingren Zhao; Taotao Yan; William Delaney; Jianming Hu
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 7.  Virological Basis for the Cure of Chronic Hepatitis B.

Authors:  Jin Hu; Junjun Cheng; Liudi Tang; Zhanying Hu; Yue Luo; Yuhuan Li; Tianlun Zhou; Jinhong Chang; Ju-Tao Guo
Journal:  ACS Infect Dis       Date:  2018-06-25       Impact factor: 5.084

8.  Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model.

Authors:  Masatoshi Kakizaki; Yuichiro Yamamoto; Motoyuki Otsuka; Kouichi Kitamura; Masatoshi Ito; Hideki Derek Kawai; Masamichi Muramatsu; Tatehiro Kagawa; Ai Kotani
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

9.  A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.

Authors:  Ya-Juan Wang; Dong Lu; Yi-Bin Xu; Wei-Qiang Xing; Xian-Kun Tong; Gui-Feng Wang; Chun-Lan Feng; Pei-Lan He; Li Yang; Wei Tang; You-Hong Hu; Jian-Ping Zuo
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

Review 10.  Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection.

Authors:  Yuchen Xia; T Jake Liang
Journal:  Gastroenterology       Date:  2018-09-19       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.